RMTG.US Regenerative Medical Technology Group Inc.
- Market cap
- USD 412K
- P/E
- -
- P/B
- 0.55x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is RMTG.US undervalued?
Graham numberThe Graham number of Regenerative Medical Technology Group Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Regenerative Medical Technology Group Inc. fundamental analysis
No fundamental analysis for Regenerative Medical Technology Group Inc. yet.
Regenerative Medical Technology Group Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Regenerative Medical Technology Group Inc.
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of stem cell therapies. The company is also involved in the treatment of patients; provision of training and seminars; and resale of kits, products, equipment, and services. In addition, it offers reoccurring application of its proces…
Full company profileRegenerative Medical Technology Group Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Regenerative Medical Technology Group Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.41K | - | 29.2K | 50.1K | 55.1K | 438K | 1.53M | 2.41M | 4.11M | 5.10M | 13.3M |
| Gross Profit | 2.41K | - | 24.4K | 35.1K | 11.1K | 150K | 877K | 1.68M | 2.82M | 2.81M | 8.46M |
| Operating Income | -603K | -451K | -501K | -255K | -448K | -9.93M | -1.18M | -715K | 81.2K | -867K | 1.59M |
| EBITDA | - | - | 218K | -1.53M | -1.69M | -10.1M | -1.02M | -3.01M | 302K | -83.6K | 4.14M |
| Net Income | -1.93M | -4.21M | -377K | -2.06M | -5.90M | -12.9M | -5.49M | -9.81M | -5.56M | -7.81M | -7.56M |
| EPS | -7.82 | -2.34 | -0.11 | -0.50 | -0.63 | -1.12 | -0.45 | -0.79 | -0.44 | -0.62 | -0.57 |
| Balance Sheet | |||||||||||
| Total Assets | 302K | 15.2K | 7.86K | 34.6K | 220K | 9.31M | 8.08M | 2.88M | 3.82M | 4.49M | 5.85M |
| Total Liabilities | 5.85M | 5.52M | 2.57M | 4.57M | 6.63M | 16.1M | 20.1M | 24.7M | 31.2M | 39.2M | 45.1M |
| Shareholders' Equity | -5.55M | -5.51M | -2.56M | -4.54M | -6.41M | -6.76M | -12.0M | -21.8M | -27.4M | -34.7M | -39.3M |
| Cash & Short-term Investments | 10.9K | 6.65K | 7.75K | 30.8K | 42.5K | 2.98M | 1.65M | 531K | 1.17M | 957K | 1.32M |
| Total Debt | 3.55M | 433K | 378K | 813K | 5.78M | 13.4M | 15.1M | 17.7M | 20.0M | 19.6M | 21.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -58.1K | -381K | -6.12K | -245K | -323K | -9.88M | -1.11M | -419K | 851K | -707K | 868K |
| Capital Expenditure | 0.00 | 0.00 | 4.00 | 4.00K | 5.00 | 4.00 | 198K | 386K | 215K | 603K | 718K |
| Free Cash Flow | -58.1K | -381K | -6.12K | -249K | -323K | -9.88M | -1.31M | -805K | 635K | -1.31M | 150K |
| Ratios | |||||||||||
| ROA | -638.7% | -27,673.0% | -4,797.1% | -5,940.9% | -2,683.1% | -138.5% | -68.0% | -340.9% | -145.6% | -174.0% | -129.3% |
| Net Profit Margin | -35,597.2% | - | -1,289.3% | -4,105.6% | -10,703.5% | -2,942.4% | -359.0% | -407.2% | -135.4% | -153.2% | -56.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Regenerative Medical Technology Group Inc. dividends
Regenerative Medical Technology Group Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:1000 on Sep 26, 2018.
Who owns Regenerative Medical Technology Group Inc.
- Insiders 7.88%
- Institutions 0.00%
- Public & others 92.12%
- Shares outstanding 13.7M
- Free float 13.2M
Regenerative Medical Technology Group Inc. company profile
- Company name
- Regenerative Medical Technology Group Inc.
- Ticker
- RMTG.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 433 Plaza Real, Boca Raton, FL, United States, 33432
- Phone
- 800 956 3935
- Website
- regenmedtechgroup.com
About Regenerative Medical Technology Group Inc.
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of stem cell therapies. The company is also involved in the treatment of patients; provision of training and seminars; and resale of kits, products, equipment, and services. In addition, it offers reoccurring application of its process using its kits and solutions. Further, it provides solutions from clinical research with the manufacturing and commercialization of viable cell therapy and immune support related products. The company was formerly known as Meso Numismatics, Inc. and changed its name to Regenerative Medical Technology Group Inc. in May 2024. Regenerative Medical Technology Group Inc. was incorporated in 1999 and is based in Boca Raton, Florida.
Regenerative Medical Technology Group Inc. management
1- Mr. David Eugene ChristensenCEO, CFO, Secretary, Principal Accounting Officer, President & Director · born 1966